Results 141 to 150 of about 1,023,792 (288)

Uptake of Pneumococcal Vaccines Among U.S. Adults After 2022 Update to Recommendations

AJPM Focus
Introduction: Updated recommendations for adult pneumococcal vaccination in the U.S. (publication date: January 27, 2022) incorporated 2 new vaccines (15- and 20-valent pneumococcal conjugate vaccines), removed 13-valent pneumococcal conjugate vaccine ...
Ahuva Averin, MPP, Jeffrey Vietri, PhD, Adriano Arguedas Mohs, MD, Sarah J. Willis, PhD, MPH, Alexander Lonshteyn, PhD, Derek Weycker, PhD   +5 more
doaj  

Pneumoccocal conjugate vaccines [PDF]

International Journal of Infectious Diseases, 2016
openaire   +2 more sources

Advanced Microfluidics for Single Cell‐Based Cancer Research

Advanced Science, EarlyView.
Cutting‐edge microfluidic platforms are transforming single‐cell cancer research. This review highlights advanced technologies, from droplet microfluidics to tumour‐chips, that enable functional and spatial single‐cell analyses. By integrating biosensing, immune components, and patient‐derived materials, these systems offer new insights into tumour ...
Adriana Carneiro, Marta Aranda Palomer, Margarida Esteves, Carolina Rodrigues, José Maria Fernandes, Francisca Oliveira, Alexandra Teixeira, Carlos Honrado, Lorena Dieguez, Sara Abalde‐Cela, Miguel Xavier   +10 more
wiley   +1 more source

Las vacunas conjugadas contra la enfermedad meningococica causadas por los serogrupos A, C, W-135, Y

VacciMonitor, 2009
Review the current evidence on available and candidate quadrivalent meningococcal conjugate vaccines. Methods: A comprehensive overview of data on the currently available A-C-W135-Y meningococcal vaccine and the results of late stage development of novel
Marcos Aurelio P. Sáfadi
doaj  

Peptide‐Based Biomaterials as a Promising Tool for Cancer Radiotherapy

Advanced Science, EarlyView.
This review provides a systematic overview of peptide‐based biomaterials in tumor radiotherapy, covering their roles as both radiosensitizers and radiopharmaceuticals. Peptide‐based radiosensitizers are generally divided into three categories: peptides as direct radiosensitizers, peptides as carriers of radiosensitizers, and targeted‐peptide‐modified ...
Qian Wang, Xinhui Chu, Jianfeng Liu
wiley   +1 more source

Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects

Advanced Science, EarlyView.
Y332D, a bispecific antibody that simultaneously blockades VEGF and TGF‐β, counteracted negative RT effects that are attributed to the upregulation of TGF‐β and VEGF, as well as further enhanced the immunostimulatory effects of RT, thereby reprograming the TME from immune “cold” to inflamed state and forming an effective in‐situ vaccine that eradicate ...
Lijuan Lyu, Ming Yi, Ji Chen, Jing Zhang, Xiaobin Ma, Xiaojun Zhang, Liang Zeng, Yan Xue, Haimei Wen, Yujiao Deng, Pengfei Zhou, Kongming Wu, Huafeng Kang, Zhijun Dai   +13 more
wiley   +1 more source

Novel Quaternary Ammonium Salt‐Linked STING Agonist Antibody‐Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off‐Target Toxicity

Advanced Science, EarlyView.
Novel quaternary ammonium salt‐linked STING agonist ADC demonstrates high potency, stability, enhanced solubility, and reduced off‐target toxicity, potently activating the STING pathway in the tumor microenvironment through the synergistic action of the Fab and Fc regions of antibodies (activity switch‐on) while exhibiting ≈20 fold lower activity in ...
Yu Long, Borui Tang, Fei Xie, Lianqi Liu, Yangyihua Zhou, Jingwen Dong, Jianfeng Wang, Cuicui Sun, Yuting Wang, Ruoqi Li, Na Zhang, Liping Li, Longlong Luo, Junhai Xiao, Wu Zhong, Dian Xiao, Hongbin Deng, Xinbo Zhou   +17 more
wiley   +1 more source

Mechanistic Foundations of KRAS‐Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment

Advanced Science, EarlyView.
KRAS mutations dynamically remodel the tumor microenvironment (TME), fostering immunosuppression, metabolic symbiosis, and stromal plasticity. This review dissects how oncogenic KRAS variants sculpt TME networks and explores actionable vulnerabilities. Emerging strategies combining KRAS inhibitors and TME‐editing approaches offer potential to dismantle
Jiayao Ma, Shenao Fu, Jun Tan, Ying Han, Yihong Chen, Xiangying Deng, Hong Shen, Shan Zeng, Yinghui Peng, Changjing Cai   +9 more
wiley   +1 more source

Advanced Cancer Immunotherapy via SMARCAL1 Blockade Using a Glucose‐Responsive CRISPR Nanovaccine

Advanced Science, EarlyView.
A glucose‐catalyzed chemodynamic strategy is proposed to activate therapeutic genome editing of SMARCAL1to improve cancer immunotherapy. This innovative design featuring Fenton reaction activity and glucose consumption ability, not only effectively synergizes to activate the cGAS‐STING pathway but also inhibits the opposing functions of interferon by ...
Yuwei Li, Yuanyi Zhang, Chenchen Li, Guoping Chen, Pir Muhammad, Yonghong Yao, Lifang Gao, Zhigang Liu, Yanli Wang   +8 more
wiley   +1 more source

Controlling Release Kinetics of an Adjuvant from a Depot Improves the Efficacy of Local Immunotherapy in Metastatic Cancer

Advanced Science, EarlyView.
We show that intratumoral release of an immunotherapy—CpG —can be tuned with molecular precision by complexing it to an elastin‐like polypeptide (ELP). Injecting ELP‐CpG and an excipient ELP into tumors drives thermally‐triggered phase separation into a micro‐scale “sponge” depot that releases CpG at rates depending on the ELP composition, which ...
Joshua J. Milligan, Rachel L. Strader, Arunangshu Chakrabarty, Max Ney, Parul Sirohi, Jonathan C. Su, Anastasia K. Varanko, Yulia Shmidov, Kalina Tsolova, Cassio Mendes Fontes, Anna Finkelstein, Rohinee Mattikalli, Yun‐Xing Wang, Lixin Fan, Xinghai Li, Smita K. Nair, Ashutosh Chilkoti   +16 more
wiley   +1 more source